Babbini M, Torrielli M V, Strumia E, Gaiardi M, Bartoletti M, De Marchi F
Arzneimittelforschung. 1975 Aug;25(8):1294-1300.
The sedative-hypnotic effects of a new benzodiazepine, 1-(2-hydroxyethyl)-3-hydroxy-7-chloro-1,3-dihydro-5-(o-fluorophenyl)-2H-1,4-benzodiazepin-2-one (SAS 643), were compared with those of flurazepam in mice and rats as well as in a double-blind clinical trial. It was found that SAS 643 has a potency 2--4 times greater than that of flurazepam while it is about one half less toxic than the latter drug. The results of the clinical trial confirm the greater activity of SAS 643 and indicate that the new benzodiazepine causes a significantly less amount of hangover than flurazepam.
一种新型苯二氮䓬类药物1-(2-羟乙基)-3-羟基-7-氯-1,3-二氢-5-(邻氟苯基)-2H-1,4-苯并二氮杂䓬-2-酮（SAS 643）的镇静催眠作用在小鼠、大鼠以及一项双盲临床试验中与氟西泮进行了比较。结果发现，SAS 643的效力比氟西泮大2至4倍，而其毒性比后一种药物低约一半。临床试验结果证实了SAS 643具有更强的活性，并表明这种新型苯二氮䓬类药物引起的宿醉现象明显少于氟西泮。
